CHICAGO -- Treatment with investigational izalontamab brengitecan (iza-bren) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC), a...
Read more























